Pravachol judicial windfall
Bristol-Myers Squibb netted an estimated $13.4 mil. from the four-day delay of generic pravastatin market entry, based on average Pravachol sales during the first quarter of $3.35 mil. per day in the U.S. Bristol's compound patent expired April 20, and FDA delays approval of Teva's 10 mg, 20 mg and 40 mg pravastatin ANDAs until April 24. The delay resulted from an April 20 D.C. Circuit Court of Appeals ruling enjoining FDA from approving pravastatin ANDAs until the court had time to review a motion for injunctive relief from Apotex. Bristol was not a party to the case. Ranbaxy, which holds 180-day exclusivity rights for the 80 mg dose, still awaits FDA approval[Editor's note: In-depth coverage of Pravachol legal proceedings appeared in 1"The Pink Sheet" DAILYApril 25. To read the article and sign up for a free trial, visit our website, 2www.ThePinkSheetDAILY.com.]...
You may also be interested in...
Device companies operating in Canada are being advised to review their internal procedures in anticipation of new postmarket requirements that come into force this year.
Valneva is scaling up manufacture of its coronavirus vaccine alongside the clinical development program, with a view to meeting its commitment to provide millions of doses for use in the UK and the EU.
The UK government says it will begin a consultation on a future falsified medicines scheme for Great Britain within a year after the passage of new legislation on medicines and medical devices. Moves are also under way to ensure the smooth supply of medicines from GB to Cyprus, Ireland, Malta and Northern Ireland.